Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results